A novel DYRK1A (Dual specificity tyrosine phosphorylation‐regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Neurochemistry

• Publication date

  2015-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/jnc.13018PMID 25556849
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.

  2014cited by this paper
• DYRK1A: a potential drug target for multiple Down syndrome neuropathologies.

  2014influential reference
• Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease

  2014cited by this paper
• Extracellular Monomeric Tau Protein Is Sufficient to Initiate the Spread of Tau Protein Pathology*

  2013cited by this paper
• Tricyclic Pyrimidines As Inhibitors of DYRK1A/DYRK1B As Potential Treatment for Down's Syndrome or Alzheimer's Disease.

  2013influential reference
• Beyond secretases: Kinase inhibitors for the treatment of Alzheimer's disease

  2013cited by this paper
• Tau protein kinases: involvement in Alzheimer's disease.

  2013cited by this paper
• Trans-Synaptic Spread of Tau Pathology In Vivo

  2012cited by this paper
• Abnormal Hyperphosphorylation of Tau: Sites, Regulation, and Molecular Mechanism of Neurofibrillary Degeneration

  2012cited by this paper
• Neurotoxicity and Memory Deficits Induced by Soluble Low-Molecular-Weight Amyloid-β1–42 Oligomers Are Revealed In Vivo by Using a Novel Animal Model

  2012cited by this paper
• Leucettines, a family of pharmacological inhibitors of DYRKs & CLKs kinases derived from the marine sponge Leucettamine B

  2012cited by this paper
• Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

  2012influential reference
• Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.

  2012cited by this paper
• β-Carboline Compounds, Including Harmine, Inhibit DYRK1A and Tau Phosphorylation at Multiple Alzheimer's Disease-Related Sites

  2011influential reference
• Harmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expression.

  2011cited by this paper
• The role of DYRK1A in neurodegenerative diseases

  2011cited by this paper
• Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.

  2011cited by this paper
• Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A

  2011cited by this paper
• High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation

  2010cited by this paper
• Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models.

  2010cited by this paper
• The amino terminus of tau inhibits kinesin‐dependent axonal transport: Implications for filament toxicity

  2009cited by this paper
• Function and regulation of Dyrk1A: towards understanding Down syndrome

  2009cited by this paper
• DYRK1A genetic variants are not linked to Alzheimer's disease in a Spanish case-control cohort

  2009cited by this paper
• Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A

  2009cited by this paper
• Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation

  2009cited by this paper
• Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing

  2008cited by this paper
• Increased Dosage of Dyrk1A Alters Alternative Splicing Factor (ASF)-regulated Alternative Splicing of Tau in Down Syndrome*♦

  2008cited by this paper
• The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome

  2008cited by this paper
• Molecular targets of (-)-epigallocatechin-3-gallate (EGCG): specificity and interaction with membrane lipid rafts.

  2008cited by this paper
• Dual‐specificity tyrosine(Y)‐phosphorylation regulated kinase 1A‐mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer’s disease

  2008cited by this paper
• Tau as a biomarker of neurodegenerative diseases.

  2008influential reference
• Biochemistry of Tau in Alzheimer’s disease and related neurological disorders

  2008cited by this paper
• Mirk/Dyrk1B in cancer

  2007cited by this paper
• Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model

  2007cited by this paper
• DYRK1A-mediated Hyperphosphorylation of Tau

  2007cited by this paper
• The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease.

  2007influential reference
• Tau-mediated neurodegeneration in Alzheimer's disease and related disorders

  2007cited by this paper
• Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.

  2005cited by this paper
• Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism.

  2005cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Tau is essential to beta -amyloid-induced neurotoxicity.

  2002cited by this paper
• Tau is essential to β-amyloid-induced neurotoxicity

  2002cited by this paper
• The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase.

  2001cited by this paper
• Cloning and characterization of DYRK1B, a novel member of the DYRK family of protein kinases.

  1999cited by this paper
• Sequence Characteristics, Subcellular Localization, and Substrate Specificity of DYRK-related Kinases, a Novel Family of Dual Specificity Protein Kinases*

  1998cited by this paper
• Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

  1986cited by this paper
• Phosphorylation affects the ability of tau protein to promote microtubule assembly.

  1984cited by this paper

• Computer-aided discovery of triazolothiadiazoles as DYRK1A-targeted neuroprotective agents.

  2025cites this paper
• Genetic knockdown of DYRK1A attenuates cognitive impairment, Aβ pathology, tauopathy and neuroinflammatory responses in mouse models of AD

  2025cites this paper
• Multi-Target Inhibitor of ZJQ- 3 F Against AChE/BACE1/GSK3β Targets Improves the Cognitive Impairment of APP/PS1/Tau Triple-Transgenic Mouse Models of Alzheimer’s Disease

  2025cites this paper
• Interplay Between Aging and Tau Pathology in Alzheimer’s Disease: Mechanisms and Translational Perspectives

  2025cites this paper
• Identification of novel DYRK1A inhibitors as treatment options for alzheimer’s disease through comprehensive in silico approaches

  2025cites this paper
• Discovery of ZJCK-6-46: A Potent, Selective, and Orally Available Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor for the Treatment of Alzheimer's Disease.

  2024cites this paper
• Furo[3,2-b]pyridine: Chemical synthesis, transformations and biological applications

  2024cites this paper
• Novel Thiazole-Fused [4,5-g] or [5,4-g]Quinazolin-8-ones and Their Quinazoline Analogues: Synthesis and Biological Evaluation

  2024cites this paper
• Over‐expression of Dyrk1A affects bleeding by modulating plasma fibronectin and fibrinogen level in mice

  2023cites this paper
• Re-Arranging the Puzzle between the Amyloid-Beta and Tau Pathology: An APP-Centric Approach

  2023cites this paper
• Discovery of Potent, Selective, and Orally Bioavailable DYRK2 Inhibitors for the Treatment of Prostate Cancer.

  2023cites this paper
• Novel Medicinal Chemistry Strategies Targeting CDK5 for Drug Discovery.

  2023cites this paper
• An inhibitor with GSK3β and DYRK1A dual inhibitory properties reduces Tau hyperphosphorylation and ameliorates disease in models of Alzheimer's disease.

  2023cites this paper
• Function and Inhibition of DYRK1A: emerging roles of treating multiple human diseases.

  2023cites this paper
• Content CN-21-5

  2023cites this paper
• FUS Alters circRNA Metabolism in Human Motor Neurons Carrying the ALS-Linked P525L Mutation

  2023cites this paper
• State‐of‐the‐art therapy for Down syndrome

  2023cites this paper
• Disruption of DYRK1A-induced hyperphosphorylation of amyloid-beta and tau protein in Alzheimer’s disease: An integrative molecular modeling approach

  2023cites this paper
• In-silico study for African plants with possible beta-cell regeneration effect through inhibition of DYRK1A

  2022cites this paper
• The chromosome 21 kinase DYRK1A: emerging roles in cancer biology and potential as a therapeutic target

  2022cites this paper
• Rational Design and Identification of Harmine‐Inspired, N‐Heterocyclic DYRK1A Inhibitors Employing a Functional Genomic In Vivo Drosophila Model System **

  2022cites this paper
• Type 2 Diabetes Mellitus and Alzheimer’s Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets

  2022influential citation
• Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase‐1A (DYRK1A), A Master Regulatory Protein Involved in Down Syndrome Brain Alterations and Mental Disability, A Key Contributor to Neurodegenerative Disorders of Alzheimer's Disease and A Potential Therapeutic Target

  2022cites this paper
• A comprehensive review of recent advances in the biological activities of quinazolines

  2022influential citation
• Local mRNA translation and cytoskeletal reorganization: Mechanisms that tune neuronal responses

  2022cites this paper
• DYRK1a Inhibitor Mediated Rescue of Drosophila Models of Alzheimer’s Disease-Down Syndrome Phenotypes

  2022cites this paper
• DYRK1A inhibitors and perspectives for the treatment of Alzheimer's disease.

  2022cites this paper
• Alterations in protein kinase networks in astrocytes and neurons derived from patients with familial Alzheimer’s Disease

  2022cites this paper
• Discovery of Hydroxybenzothiazole Urea Compounds as Multitargeted Agents Suppressing Major Cytotoxic Mechanisms in Neurodegenerative Diseases.

  2021cites this paper
• A Brief Overview of Pathological Tau and Inhibitors and Modifiers of Tau Aggregation for Treatment of Tauopathies

  2021influential citation
• DYRK1A inhibitors for disease therapy: Current status and perspectives.

  2021cites this paper
• Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome

  2021cites this paper
• GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways

  2021cites this paper
• Protective effects of a small molecule inhibitor ligand against hyperphosphorylated tau-induced mitochondrial and synaptic toxicities in Alzheimer disease.

  2021cites this paper
• Multi-omic profiling reveals the ataxia protein sacsin is required for integrin trafficking and synaptic organization

  2021cites this paper
• Multifaceted Alzheimer’s Disease: Building a Roadmap for Advancement of Novel Therapies

  2021cites this paper
• Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview

  2021cites this paper
• Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors.

  2021cites this paper
• Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.

  2021cites this paper
• Sulfur-containing therapeutics in the treatment of Alzheimer’s disease

  2021cites this paper
• The Alteration of Neurogenesis and Pathological Markers in Alzheimer's Disease After Deep Brain Stimulation.

  2021cites this paper
• Kinase Signaling in Dendritic Development and Disease

  2021influential citation
• Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review.

  2021cites this paper
• Protein phosphatase PPM1B inhibits DYRK1A kinase through dephosphorylation of pS258 and reduces toxic tau aggregation

  2020cites this paper
• Defining the Neural Kinome: Strategies and Opportunities for Small Molecule Drug Discovery to Target Neurodegenerative Diseases

  2020cites this paper
• Structure–Activity Relationships and Biological Evaluation of 7-Substituted Harmine Analogs for Human β-Cell Proliferation

  2020cites this paper
• Emerging roles of DYRK2 in cancer

  2020cites this paper
• Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133.

  2020cites this paper
• Synthesis and Biological Validation of a Harmine-based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.

  2020cites this paper
• A Dual Inhibitor of DYRK1A and GSK3β for β-Cell Proliferation: Aminopyrazine Derivative GNF4877.

  2020cites this paper
• The novel DYRK1A inhibitor KVN93 regulates cognitive function, amyloid-beta pathology, and neuroinflammation.

  2020cites this paper
• Pharmacologic and genetic approaches define human pancreatic beta cell mitogenic targets of DYRK1A inhibitors.

  2019cites this paper
• Repurposing nitrocatechols: 5-Nitro-α-cyanocarboxamide derivatives of caffeic acid and caffeic acid phenethyl ester effectively inhibit aggregation of tau-derived hexapeptide AcPHF6.

  2019cites this paper
• Estrogen‐related receptor β activation and isoform shifting by cdc2‐like kinase inhibition restricts migration and intracranial tumor growth in glioblastoma

  2019cites this paper
• Design, Synthesis, and In Vitro Biological Activities of a Bio-Oxidizable Prodrug to Deliver Both ChEs and DYRK1A Inhibitors for AD Therapy

  2019cites this paper
• Downregulated Wnt/β-catenin signalling in the Down syndrome hippocampus

  2019cites this paper
• Hypothesis and Theory: Circulating Alzheimer's-Related Biomarkers in Type 2 Diabetes. Insight From the Goto-Kakizaki Rat

  2019cites this paper
• The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region

  2019cites this paper
• DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291

  2019cites this paper
• Current and Emerging Pharmacological Targets for the Treatment of Alzheimer’s Disease

  2019cites this paper
• Therapeutic Potential of the Hsp90/Cdc37 Interaction in Neurodegenerative Diseases

  2019cites this paper
• Biological Characterization of 8-Cyclopropyl-2-(pyridin-3-yl)thiazolo[5,4-f]quinazolin-9(8H)-one, a Promising Inhibitor of DYRK1A

  2019cites this paper
• Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease

  2019cites this paper
• Directed evolution of a picomolar-affinity, high-specificity antibody targeting phosphorylated tau

  2018cites this paper
• Effect of ferric citrate on amyloid‐beta peptides behavior

  2018cites this paper
• Implications de la protéine DYRK1A dans la pathologie Alzheimer et développement de stratégies thérapeutiques

  2018cites this paper
• Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design

  2018cites this paper
• Tau Aggregation, Conformational Selection, and Inhibition

  2018cites this paper
• Insights into the Molecular Mechanisms of Alzheimer’s and Parkinson’s Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology

  2018cites this paper
• Tau Proteins and Tauopathies in Alzheimer’s Disease

  2018cites this paper
• Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A.

  2018cites this paper
• DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective.

  2018cites this paper
• Involvement of calpain in the neuropathogenesis of Alzheimer’s disease

  2018cites this paper
• Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification.

  2018cites this paper
• Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives.

  2018cites this paper
• Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.

  2018cites this paper
• Development of Kinase Inhibitors via Metal-Catalyzed C–H Arylation of 8-Alkyl-thiazolo[5,4-f]-quinazolin-9-ones Designed by Fragment-Growing Studies

  2018cites this paper
• Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A

  2018cites this paper
• Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.

  2018cites this paper
• Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.

  2018cites this paper
• Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.

  2018cites this paper
• Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome

  2017cites this paper
• Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.

  2017cites this paper
• Increased levels of plasma total tau in adult Down syndrome

  2017cites this paper
• Developing DYRK inhibitors derived from the meridianins as a means of increasing levels of NFAT in the nucleus.

  2017cites this paper
• A Requirement for Mena, an Actin Regulator, in Local mRNA Translation in Developing Neurons.

  2017influential citation
• Molecular Features of the YAP Inhibitor Verteporfin: Synthesis of Hexasubstituted Dipyrrins as Potential Inhibitors of YAP/TAZ, the Downstream Effectors of the Hippo Pathway

  2017cites this paper
• Structure‐Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition

  2017cites this paper
• Dyrk1 inhibition improves Alzheimer's disease‐like pathology

  2017cites this paper
• Overexpression of the DYRK1A Gene (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A) Induces Alterations of the Serotoninergic and Dopaminergic Processing in Murine Brain Tissues

  2017cites this paper
• Inhibition of DYRK1A disrupts neural lineage specificationin human pluripotent stem cells

  2017cites this paper
• Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome

  2017cites this paper
• MTH1 as a nucleotide pool sanitizing enzyme: Friend or foe?☆

  2017cites this paper
• In vivo and ex vivo analyses of amyloid toxicity in the Tc1 mouse model of Down syndrome

  2017influential citation
• Tyrosine Regulates β-Sheet Structure Formation in Amyloid-β42: A New Clustering Algorithm for Disordered Proteins

  2017cites this paper
• Roles of tau protein in health and disease

  2017cites this paper
• An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f] quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases.

  2016cites this paper
• Genetics of Frontotemporal Lobar Degeneration: From the Bench to the Clinic

  2016cites this paper
• Pd-Catalyzed and Copper Assisted Regioselective Sequential C2 and C7 Arylation of Thiazolo[5,4-f]quinazolin-9(8H)-one with Aryl Halides.

  2016cites this paper
• DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome

  2016cites this paper